SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years
BREXAFEMME® (ibrexafungerp tablets) Product Image #1 BREXAFEMME® (ibrexafungerp tablets) Package Image #2 BREXAFEMME® (ibrexafungerp tablets) Product Logo SCYNEXIS Logo SCYNEXIS...